Dr. Becerra on Ribociclib/Letrozole in ER+/HER2- Breast Cancer

Carlos Becerra, MD
Published: Wednesday, Jul 20, 2016


Carlos Becerra, MD, physician, Texas Oncology, discusses a study examining the combination of ribociclib and letrozole in patients with ER-positive, HER2-negative advanced breast cancer.

To enroll on the trial, patients must have progressed on estrogen receptor inhibitors, Becerra explains. Patients were treated with the combination to determine whether treatment with the CDK 4/6 inhibitor would prevent resistance to letrozole.

Results showed that the combination demonstrated clinical activity as well as an acceptable safety profile in patients, with an overall response rate of 39%.

Carlos Becerra, MD, physician, Texas Oncology, discusses a study examining the combination of ribociclib and letrozole in patients with ER-positive, HER2-negative advanced breast cancer.

To enroll on the trial, patients must have progressed on estrogen receptor inhibitors, Becerra explains. Patients were treated with the combination to determine whether treatment with the CDK 4/6 inhibitor would prevent resistance to letrozole.

Results showed that the combination demonstrated clinical activity as well as an acceptable safety profile in patients, with an overall response rate of 39%.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Publication Bottom Border
Border Publication
x